Complexo Hospitalario Universitario de Vigo
Centro de atención
Hospital Universitario San Jorge de Pereira
Pereira, ColombiaPublicacións en colaboración con investigadores/as de Hospital Universitario San Jorge de Pereira (10)
2022
-
Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry
Journal of Clinical Medicine, Vol. 11, Núm. 2
-
Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII)
Journal of Clinical Medicine, Vol. 11, Núm. 24
2016
-
Intraoperative transfusion practices in Europe
British Journal of Anaesthesia, Vol. 116, Núm. 2, pp. 255-261viii
2010
-
Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists
Annals of the Rheumatic Diseases, Vol. 69, Núm. 10, pp. 1751-1755
2008
2007
-
Baseline serum hepatitis C virus (HCV) RNA level and response at week 4 are the best predictors of relapse after treatment with pegylated interferon plus ribavirin in HIV/HCV-coinfected patients
Journal of Acquired Immune Deficiency Syndromes, Vol. 45, Núm. 4, pp. 439-444
-
Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV/HIV-coinfected patients
Journal of Viral Hepatitis, Vol. 14, Núm. 6, pp. 387-391
-
Premature treatment discontinuation in HIV/HCV-coinfected patients receiving pegylated interferon plus weight-based ribavirin
Antiviral Therapy, Vol. 12, Núm. 4, pp. 469-476
-
Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: The PRESCO trial
AIDS Research and Human Retroviruses, Vol. 23, Núm. 8, pp. 972-982
2005
-
Impact of ribavirin exposure on early virological response to hepatitis C therapy in HIV-infected patients with chronic hepatitis C
Antiviral Therapy, Vol. 10, Núm. 5, pp. 657-662